Clinical Trial Update: A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 dose-escalation and dose-optimization study to evaluate the safety and efficacy of CID-103 in adults with chronic immune thrombocytopenia; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• CID-103 (anti-CD38 antibody)

Snippet

Sponsor: CASI Pharmaceuticals, Inc. | Conditions: Chronic Immune Thrombocytopenia | Phase 1, Phase 2 | Status: RECRUITING